GSK/Theravance Press On With LABA After Cmtes. Cut Asthma Indication
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Many pharmaceutical firms' corporate plans for developing new asthma products that combine long-acting beta agonists with inhaled corticosteroids are not seriously affected by the recommendation of three FDA advisory committees to eliminate the asthma indication for single-entity LABA products